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Abstract
The interpretation of genomic variants has become one of the paramount
challenges in the post-genome sequencing era. In this review we summarize
nearly 20 years of research on the applications of information theory (IT) to
interpret coding and non-coding mutations that alter mRNA splicing in rare and
common diseases. We compile and summarize the spectrum of published
variants analyzed by IT, to provide a broad perspective of the distribution of
deleterious natural and cryptic splice site variants detected, as well as those
affecting splicing regulatory sequences. Results for natural splice site mutations
can be interrogated dynamically with Splicing Mutation Calculator, a
companion software program that computes changes in information content for
any splice site substitution, linked to corresponding publications containing
these mutations. The accuracy of IT-based analysis was assessed in the
context of experimentally validated mutations. Because splice site information
quantifies binding affinity, IT-based analyses can discern the differences
between variants that account for the observed reduced (leaky) versus
abolished mRNA splicing. We extend this principle by comparing predicted
mutations in natural, cryptic, and regulatory splice sites with observed
deleterious phenotypic and benign effects. Our analysis of 1727 variants
revealed a number of general principles useful for ensuring portability of these
analyses and accurate input and interpretation of mutations. We offer
guidelines for optimal use of IT software for interpretation of mRNA splicing
mutations.
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Introduction
Pre-mRNA splicing is a necessary step in the production of a func-
tional protein product. It consists of the recognition of intron/exon 
boundaries, and the subsequent excision of the introns. It is impor-
tant to distinguish between alternate splicing isoforms and mutant 
splice forms. The former consists of using different combinations 
of splice sites for the same gene. It is estimated to occur in over 
60% of human genes, some of which will have multiple alternate 
isoforms1,2. For example, NF1 (responsible for neurofibromatosis 
type 1 disease) is reported to produce 46 splice variants3. The cell 
regulates this naturally occurring process through the availability 
of tissue-specific splice factors. Alternative splicing is not gener-
ated by changes in the unspliced RNA sequence, whereas muta-
tions that produce non-constitutive splice forms are the result of 
dysregulation of natural splice site recognition. Mutations can have 
various consequences to RNA processing, such as exon skipping, 
cryptic splicing, intron inclusion, leaky splicing, or less frequently, 
introduction of pseudo-exons into the processed mRNA. A broad 
range of molecular phenotypes are possible depending on the type 
and severity of the mutation, making it imperative to understand 
the consequences of splicing mutations. For the purposes of this 
review, we consider sequence changes in genes that affect transcript 
structure or abundance to be mutations, regardless of their allele 
frequencies. Although spliceosomal recognition and RNA binding 
factors are operative in mutation-derived and normal alternative 
mRNA splicing events, this review is focused on aberrant sequence 
changes that alter constitutive splicing, and often result in clinically 
abnormal phenotypes.
The process of U1/U2-based mRNA splicing involves the recogni-
tion of a number of key sequence components4,5, with exons defined 
by both intronic and exonic features4,6. The intronic sequence 
flanking the 3´ end of an intron is termed the donor site and the 5´ 
end, the acceptor site. In typical mRNA splicing, the natural donor 
and acceptor splice sites of an exon span intervals of 10 and 28 
bases in length, respectively. It is a common misconception that 
these sequences (especially the dinucleotides immediately intronic to 
the exon) are invariant. Although highly conserved, these sequences 
vary at different splice junctions within a gene as well as between 
genes. The particular combination of nucleotides at each position 
within the same splice site determines its overall strength, which 
dictates the likelihood of recognition by the U1 and U2 spliceo-
somes. Indeed, the recognition of internal exons is reliant on the 
strength of both natural splice sites7. The alteration of exonic splic-
ing signals (described in the following paragraph) by coding vari-
ants is common (~25%)8, which plays a significant role in disease 
due to aberrant mRNA processing. The creation and loss of bind-
ing sites for these splicing factors can also result in small changes 
in mRNA structure and overall gene expression, and is part of the 
diverse tissue-specific regulatory ecosystem of the cell9.
In addition, binding sites for splicing regulatory elements have been 
shown to reside over a range of distances from the corresponding 
natural splice sites10; the impact of these sites appears to be related 
to their binding affinities to the cognate RNA binding proteins and 
to their distance from the proximate intron/exon boundary11. Rec-
ognition sites for these regulatory proteins can reside either within 
introns or exons. Those within exons are commonly referred to as 
exonic splice enhancers or silencers (ESE or ESS, respectively), 
whereas the corresponding designations for intronic elements are 
ISE or ISS. Sequence variants affecting these protein-binding sites 
(or mutations in the binding proteins themselves) have been docu-
mented as contributing to aberrant splicing and pathogenic phe-
notypes. We focus on variants occurring in cis with target genes, 
as opposed to those in the splicing complex (in trans), leading 
to abnormal splicing. The efficiency and specificity of splicing 
depends on the combination of natural splice site strengths and 
the binding of splicing regulatory proteins that orchestrate exon 
recognition12.
Mutations that affect pre-mRNA splicing account for at least 15% 
of disease-causing mutations13 with up to 50% of all mutations 
described in some genes14,15. Interpreting the effects that these vari-
ants have on splicing is not straightforward because natural and reg-
ulatory splice sites exhibit considerable sequence variation. Further-
more, performing in vitro experiments to verify the consequences 
of each variant is costly and time consuming, and may not be prac-
tical. In silico prediction methods have become essential resources 
for analyzing these variants. Software programs for splicing analy-
sis use a wide variety of bioinformatics approaches. Several splice 
site prediction tools compare the predicted mutant sequence to a 
consensus sequence, based on a set of functional acceptor or donor 
splice sites16. A drawback of this approach is that low-frequency nucle-
otides present in functional splice sites are not represented, which 
can lead to misinterpretation and false-positive mutation predictions. 
One example of this was illustrated by Rogan and Schneider (1995), 
in which the MSH2 (hereditary non-polyposis colon cancer) variant 
described by Fishel et al. (1993), IVS12-6T>C, was predicted to be 
benign, despite being located 6 nt from the natural acceptor splice 
junction17,18. The consensus sequence fails to indicate that C and T 
            Amendments from Version 1
All figure and table titles have been adjusted to reflect the order in 
which they appear in the main text. Both Supplementary Table 5 
and the Splicing Mutation Calculator (SMC) software now include 
all benign natural site variants, and Supplementary Table 6 was 
added which includes these benign variants. In Supplementary 
Table 4, we found a small number of variants which were 
excluded from the original list of Deleterious Natural Site Variants 
(used to create Figure 1B) due to inconsistent formatting. 
This has been corrected, Figure 1 has been updated, and the 
correlation coefficients were recalculated (slightly increasing this 
value for donor site mutations; p.7 last paragraph). The citations 
of references which have changed since the initial submission 
have been updated. Additionally, since the original submission, 
all of software programs described, excluding SMC, have been 
integrated into a single application. The corresponding URLs 
have been changed to www.mutationforecaster.com. Finally, all 
tables were edited to improve uniformity of presentation.
Although this article exceeds the lengths of other reviews 
published in F1000Research, we wanted the paper to be as 
comprehensive as possible. We structured the article to enable 
readers to find and read particular sections of interest, without 
having familiarity with all of the preceding material. 
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at this position are nearly equally probable, which reclassified this 
transition as a polymorphism rather than a pathogenic variant. This 
conclusion is supported by evidence that ~10% of normal individu-
als without predisposition to non-polyposis colon cancer harbour 
this alternate allele19.
Over the last 20 years, we and others have developed an informa-
tion theory (IT)-based approach for prediction of splicing muta-
tions, and their impact on mRNA structure and abundance. The 
effects of these mutations is founded on the formal relationship 
between IT and the second law of thermodynamics, in that the 
change in information ascribed to a sequence variant within a 
splice site is directly related to thermodynamic entropy and free 
energy of binding20,21. A weight matrix consisting of the Shannon 
information (product of the probability of each nucleotide and 
–log2 of its probability) at each position of the splice site is con-
structed. The individual information for a splice site (Ri, in bits) 
is defined as the dot product of this weight matrix and the unitary 
vector of a particular splice site sequence. The magnitude of the 
information content of a nucleotide within a given site is an indi-
cation of its level of conservation relative to a set of functional 
sites. This method retains all of the sequence variability inher-
ent in each model of donor and acceptor splice sites. By contrast, 
each base in the consensus sequence has the maximum Ri value, 
which is actually rare in the human genome, and is generally not 
representative of the preponderance of natural splice sites. Prior 
to the introduction of IT-based approaches, consensus sequence-
based methods were widely used16. The use of neural networks, 
trained on sequences experimentally determined to be “bound” 
and “unbound”, was another early approach used to predict splice 
sites22. However, these unbound sets of sequences are known to 
harbour some contaminating functional sites23,24, which can limit 
the sensitivity and specificity of these networks25.
There are instances when IT does not accurately predict the conse-
quences of a splice variant. This can often be attributed to instances 
involving multiple sites or multiple regulatory factors, which are 
not components of current splicing models. In addition, splicing 
regulatory proteins can share overlapping and degenerate binding 
sites, and may exert conflicting effects (for example, serine-arginine 
[SR] vs. hnRNP proteins), making in silico prediction less reliable 
and less accurate in these cases26. Finally, functional cryptic splic-
ing motifs occurring deep within the introns can be challenging to 
identify, because they tend to be less well conserved than natural 
splice sites27,28.
Nevertheless, a number of authors have recommended IT methods 
for analysis of splice site variants (N = 29; Supplementary Table 1). 
In fact, this approach has been described as equivalent to using a 
general reference textbook as a diagnostic tool, which comple-
mented by functional assays, may provide a complete molecular 
diagnosis29. Most of the applications of IT for splicing mutation 
analysis have involved predominantly rare diseases, as well as some 
low frequency variants associated with more common genetic con-
ditions. This is because IT has been used to assess how well com-
puted changes in binding affinity conform to levels of expression 
and/or patient phenotypes.
Many IT studies have focused on sequence variants in individual 
disorders or genes. Our synopsis of the broader implications of this 
work sets the stage for this compilation of peer-reviewed variants 
with accompanying IT analyses. We cover all publications retrieved 
through PubMed and Google Scholar that cite the use of IT (N = 367; 
Supplementary Bibliography) before September 2014. These items 
include primary research articles, review articles, presentations, and 
theses. Of all references, 216 publications reported variants or other 
results or analyses pertinent to this review (Supplementary Table 2). 
In the remaining studies, analyses were either not performed, insuf-
ficient information was provided to reproduce the reported result, 
or authors described unrelated applications of IT-based analysis. 
We summarize the spectrum of variants analyzed to obtain a global 
perspective of splicing mutations resulting in genetic disease. We 
also highlight common errors that can occur in variant analysis and 
interpretation, and offer guidelines for optimal use of our software 
programs for interpretation of splicing mutations.
Information theory and splice site analysis
IT was first introduced by Claude Shannon in 1948 and is now used 
in a variety of disciplines to express the average number of bits 
(i.e. the information content) needed to communicate symbols in a 
message30. Bits are the basic unit used in computing and can have 
one of two values (typically the answer to a yes/no, true/false, or 
+/- problem). In nucleic acid molecular biology, the symbols in 
the message comprise a group of related, aligned sequences, with 
the average number of bits in the set corresponding to the amount 
of information in the message. This is determined from the infor-
mation content at each position in the sequence, summed over all 
positions31. The average information is depicted graphically by 
a sequence logo, which stacks the individual nucleotides at each 
position ranked by frequency, and where the height of the stack is 
the position-specific contribution to the average information32. If 
the set of sequences are functional binding sites recognized by the 
same factor, the individual information in each site (i.e. Ri value) is 
related to thermodynamic entropy, and thus, to the free energy of 
binding21.
The information content of a nucleic acid binding site is related to 
the affinity of its interaction with proteins and other macromolecular 
complexes, such as in the case during mRNA splicing21. Informa-
tion theory-based position weight matrices (PWM; Ri [b,l] - also 
referred to as a ribl - where b and l correspond to the nucleotide and 
position in the splice site) can be determined for a set of known 
binding sites, in this case, for the purpose of calculating individual 
and average sequence information31. Figure 1 shows an example of 
sequence logos for the canonical acceptor (or 3´, recognized by the 
U2 spliceosome) and donor (or 5´, recognized by the U1 spliceo-
some) splice sites, computed from the majority of constitutive sites at 
annotated splice junctions in the human genome33. The information 
contained within the natural splice donor site is distributed between 
the last codon of each exon and the adjacent 6 nucleotides of intronic 
sequence, whereas the acceptor sites are almost entirely intronic, 
extending 26 nucleotides upstream from the exon boundary.
The distributions of Ri values for these sets are approximately 
Gaussian, with a couple of important exceptions, namely the 
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distribution has defined upper and lower bounds21. The upper limit 
corresponds to the consensus sequence, as it is not possible to 
have stronger binding than an exact match to this sequence. The 
theoretical lower limit corresponds to Ri = 0 bits. An Ri value less 
than zero implies that energy would be required (ΔG > 0 kcal/mol) 
for a stable binding complex to form (i.e. that the event would not 
occur spontaneously without an exogenous source of energy). The 
minimum strength site is zero bits, the equilibrium state (ΔG = 0). 
Assuming the contacts at each position in the same binding site 
form independently, this approach is accurate and quantitative. 
Altering a nucleotide with high information (implying high preva-
lence and conservation at that position) will have a greater impact 
on binding, than if a less-well conserved base were altered. The 
change in information due to a mutation in a site (ΔRi) is the differ-
ence between Ri,final and Ri,initial values, where Ri,final is the information 
of the sequence containing the variant, and Ri,initial the information 
of the reference (wild-type) sequence. The minimum fold change in 
binding affinity resulting from the mutation is an exponential func-
tion based on ΔRi, or ≥ 2ΔRi (Ref. 21).
Software resources
Delila package/system
Information analysis was originally performed using the Delila 
sequence analysis system, which included a language to process 
nucleic acid sequences, and a library of sequence tools to retrieve 
and process various types of sequence data34,35. Tools to measure 
Figure 1. Distribution of deleterious natural site variants relative to information content. A) The sequence logo for human acceptor and 
donor splice sites based on the positive (+) strand of the October 2000 (hg5) genome draft. The logo shows the distribution of information 
contents (Ri in bits) at each position over the region of 28 nucleotides for acceptor [-25, +2] and 10 nucleotides for donor [-3, +6] from the 
first nucleotide of the splice junction (position 0). Nucleotide height represents its frequency at that position. The horizontal bar atop each 
stack indicates the standard deviation at that position. This figure was modified from Rogan et al. (2003) to include splice sites in genes on 
both strands of the annotated human reference genome33. B) The distribution of deleterious single-nucleotide variants reported at the natural 
acceptor (left) and donor (right) splice sites. The variants used to populate this graph (Supplementary Table 4) were included only if they were 
reported to negatively affect splicing (N = 431 for acceptors, 604 for donors). The image was aligned to the sequence logo (A) to illustrate 
potential correlation of number of splicing variants at a position to the information content at that position.
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information content of nucleic acid sequences were subsequently 
added to Delila31. Initially, models of information content of bacte-
riophage T7 RNA polymerase binding sites and other bacterial con-
trol systems were studied, and mRNA splice sites were subsequently 
developed31,36. Later, tools to display binding sites as sequence logos 
of average information, and sequence walkers showing individual 
information - were incorporated into Delila23,32. The Automated 
Splice Site Analysis (ASSA) server introduced in 2004, and its suc-
cessor, the Automated Splice Site and Exon Definition Analysis 
server (ASSEDA), have been freely available throughout the last 
decade, and have been used for IT-based calculations on nucleic acid 
sequences for the preceding 20 years37,38. Both ASSA and ASSEDA 
still use the Delila program suite to retrieve sequences, calculate infor-
mation content, and create sequence walker representations of indi-
vidual binding sites. ASSEDA is now available in a common interface 
with the other information theory-based tools described below at 
www.mutationforecaster.com.
ASSA/ASSEDA
To simplify mutation analysis, we built a web interface for variant 
analysis using Delila software as the processing backbone37. Our 
aim was to standardize and facilitate IT-based mutation analysis by 
using Human Genome Variation Society (HGVS)-approved variant 
nomenclature (which has since become the worldwide standard), 
employing server-based retrieval/processing, and reporting results 
as concise predictions in both tabular and sequence walker dis-
play formats. Initially, ASSA results described mutations in rela-
tion to genome annotations from the first finished genome release 
(hg15)37. While many publications cited this version of ASSA for 
novel splicing mutation analysis, continued improvements have 
introduced more accurate reference sequences, annotations, and 
models (for both constitutive and regulatory splice sites) based on 
more comprehensive sets of binding sites. The ASSA server con-
tained the original donor and acceptor information position weight 
matrices derived by manual curation of GenBank entries, murine 
donor and acceptor weight matrices, a subset of splicing enhancer 
elements (SF2/ASF, SC35 and SRp40), and the lariat branch- 
point recognition sequence36. ASSA reported the strengths of all 
potential sites predicted within the window selected by the user, 
highlighted those with the largest changes in Ri, and computed 
the minimum fold change in binding affinity for each mutation or 
polymorphism. Tabular results were colour-coded. Unaltered sites 
above and below the Ri,min (described in Minimum splice site infor-
mation content and exceptions) were highlighted grey and white, 
respectively. Pre-existing sites abolished by the variant (where 
Ri,final < Ri,min) were marked in red, while leaky natural sites (Ri,final 
≥ Ri,min) were highlighted in blue. Cryptic sites that were created, 
strengthened, or weakened were highlighted in pink, green and 
teal, respectively. The server parsed any mutation type described 
precisely by the HGVS notation, including substitutions, inser-
tions, deletions, and combinations of these changes39. Recapitu-
lating variants described in articles before these guidelines were 
widely adopted proved to be time-consuming and error-prone25. 
Multiple binding factors had to be analyzed simultaneously; 
however, results were reported independently. The analysis did 
not consider other factors relevant to splice site recognition, such 
as the resulting exon size, or potential formation of cryptically 
spliced exons.
ASSEDA, the successor software to ASSA, provides a new isoform-
oriented type of mutation interpretation, updates the coordinate 
system to HG19 (GRCh37), adds current gene and single nucle-
otide polymorphism (SNP) annotations (dbSNP135), and provides 
additional ribls for other splicing regulatory sites (SRp55, TIA1, 
ELAVL1, hnRNP A1, hnRNP H, and PTB). All models, except 
those for SRp55 and hnRNPH, have been built using sequences from 
publicly available CLIP-seq data, and are based on a larger number 
of binding site sequences. They have been tested by comparing pre-
dictions to validated binding sites from published primary literature, 
and to any splice-altering variants found within them38. ASSEDA 
introduces in silico exon definition analysis by computing the total 
splicing information across an exon38. Total exon information (Ri,total) 
is the sum of the corresponding donor and acceptor Ri values, and 
corrected for the gap surprisal term, which is based on the length 
of the potential exon formed using those sites (from RefSeq)40. The 
gap surprisal function is based on the genome-wide distribution 
of constitutive exon lengths, also known as self-information. This 
term ensures that exons are computationally defined using donor 
and acceptor splice sites in close proximity40,41.
Exons of uncommon length lead to large negative gap surprisal 
terms, which reduces Ri,total. When applied to predicted exons that 
activate a cryptic splice site, comparison of Ri,total values can more 
accurately predict cryptic site use than the strength of this site alone. 
The gap surprisal term decreases the predicted Ri,total value of par-
ticularly long internal exons (eg. the 3.4 kb long exon 11 of BRCA1; 
Ri,total = 1.4 bits), which tends to compensate for this effect with 
strong splice sites and other sequence elements that enhance natural 
splice site recognition and suppress internal cryptic splice sites.
The exon definition paradigm extends to the assessment of the 
impact of mutations in ESE/ISS elements. ASSEDA calculates 
Ri,total by adding the Ri value of a regulatory splicing element to the 
contributions of constitutive splice sites, and applying a second 
gap surprisal term based on the frequency of distance from the 
splicing element to the nearest natural site. Currently, the effect of 
only one splicing factor can be evaluated by the software at a time, 
although the approach itself is generalizable to multiple regula-
tory binding sites. If a variant causes changes in the Ri values of 
multiple sites, such as the simultaneous creation of both splicing 
enhancer and repressor elements, there will be less confidence in 
ASSEDA’s predictions.
Two distinct sets of IT-based models for donors and acceptors are 
available on ASSEDA. The manually curated ribls were originally 
determined from 1799 donor and 1744 acceptor sites36. We subse-
quently derived a set of ribl matrices from genome-wide exon anno-
tations33. These models were automatically curated using the criteria 
that enforced Ri > 0 for correctly annotated sites. The resultant mod-
els consisted of 108,079 acceptor and 111,772 donor splice sites, 
however these were not formally implemented on the ASSA server 
until 201133. These genome-wide models are used in the calculation 
of Ri,total values. The ΔRi values for a single nucleotide splicing vari-
ant are similar for both sets of models. Variants having opposite pre-
dicted effects between the respective donor or acceptor ribls have not 
been reported. In general, the genome-wide models report slightly 
lower information contents, however the frequencies of nucleotides 
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at the 5´ end of the acceptor site differ significantly. This results 
in differences in the weights in the -4 to -20 nt region between the 
manually-curated and the genome-wide acceptor ribl matrix, which 
can significantly lower Ri values based on the genome-wide model. 
In the genome, thymine is more prevalent than cytosine at these 
positions and has a higher positive contribution to the overall Ri. 
This can account for up to a 1.97 bit difference between the mod-
els. Guanine nucleotides within this sequence window significantly 
lower the Ri values computed from the genome-wide acceptor ribl, 
as well. While these differences contribute only a 0.1–0.4 bit dif-
ference to the Ri per nucleotide, the cumulative effect of multiple 
differences within this window can lead to significant differences 
between the acceptor Ri values.
Shannon Pipeline and Veridical
High-throughput DNA sequencing is generating a deluge of novel 
variants in patients with genetic diseases, most of which currently 
have unknown significance (VUS). For example, 20% of the patients 
with Pelizaeus-Merzbacher disease possess VUS in the PLP1 gene, 
among which are single or compound heterozygous, rare pathogenic 
mutations42. Many solutions have been proposed, however predic-
tion of pathogenicity by bioinformatic analyses is often inaccurate43. 
The Shannon Human Splicing Mutation Pipeline software predicts 
mutations at genome scale to predict which variants may alter 
mRNA splicing and is based on the same principles and IT models 
used in ASSA and ASSEDA44. However, this software processes ~5 
million substitutions and/or indels in 10–15 minutes. While initially 
only available for the CLC-Bio Genomics platform, this software is 
now also offered as a web service in the suite of programs available 
through Mutation Forecaster (www.mutationforecaster.com). Vari-
ants are batched in standard variant call format (VCF). The pipeline 
reports any genic variant that affects a known natural site or a cryptic 
site where Ri,initial or Ri,final are ≥ 0 bits and ΔRi ≥ 1.0 bits, however 
more stringent criteria for selecting variants with significant infor-
mation changes can be applied.
In Shirley et al. (2013), all variants from the complete genomes 
of three cancer cell lines (A431, U2OS, U251; N = 816,275) were 
analyzed44. Variants that were common (≥ 1%) were removed. Vari-
ants that weakened natural sites, or strengthened cryptic sites to 
levels comparable to or exceeding the strength to the nearest natural 
site, were flagged. Variants that strengthen a natural site could have 
an effect on the splicing profile of a gene (i.e. reduce the frequency 
of exon skipping for the corresponding exon), but are less likely to 
cause a deleterious phenotype. The overall fraction of mutations 
flagged, after filtering out distant cryptic sites and small ΔRi val-
ues, averaged 0.016%, illustrating how the software can be used for 
prioritizing variants. Some of the prioritized variants occurred in 
genes with known defective functional and biochemical pathways 
in these cancer cell types, i.e. cytokine signalling (in A431), DNA 
replication and cell cycle (in U2OS). Natural splice mutations were 
confirmed by expression data to a greater extent than either leaky or 
cryptic splice site variants.
In a complete cancer cell line genome, the number of cryptic sites 
with altered Ri values greatly exceeds the number of affected natu-
ral splice sites. Many of these are weak decoys, which can occur 
throughout genes. Using the principle that novel cryptic sites that 
are likely to be activated must compete with the natural splice site 
for spliceosomal recognition, the relevant cryptic sites are restricted 
to those with Ri values comparable to or greater than the corre-
sponding strength of the adjacent natural site of the same polarity25. 
Additionally, the proximity of potential cryptic sites to the natu-
ral site should be considered in assessing whether an exon could 
be formed with the natural splice site of opposite polarity. Cryptic 
sites that are considerably weaker than the nearest natural site of 
the same type, or cryptic sites that would lead to unusually large 
exons, diminish the likelihood of cryptic site activation. Benaglio 
et al. (2014) used the Shannon Pipeline to screen 303 sequenced 
patients and flagged five variants that each strengthened or created 
a different cryptic site45. While comparable in strength to the natural 
site, these were all distant (> 400 nt away) and thus, less likely to 
be recognized. The authors also stated that the ΔRi values for three 
of these sites were discordant with results obtained with NNSplice, 
a neural network-based splicing prediction program. In fact, both 
the Shannon Pipeline and NNSplice demonstrated strengthening of 
these decoy cryptic splice sites.
Shirley et al. (2013) evaluated the predictions of the Shannon 
Pipeline by manually inspecting RNAseq data for each variant 
with significant information changes in each cell line44. However, 
manual review is unfeasible for many large datasets, especially 
from tumors, because of the large numbers of potential somatic 
mutations affecting splicing in each genome. Veridical, an in silico 
method for validation of DNA sequencing variants that alter mRNA 
splicing, has been developed to provide high throughput, statisti-
cally-robust unbiased evaluation based on RNAseq data46. The 
method has been implemented as software for analysis of potential 
splicing variants from large datasets and catalogues their effects. 
Veridical takes Shannon Pipeline output from predicted genomic 
variants with effects on splicing and performs a case-control anal-
ysis of corresponding expressed transcripts that cover the same 
genomic region, taken from normal tissues. Upon Yeo-Johnson 
transformation of the expressed read count distribution, parametric 
statistics are used to compare normal and abnormal mRNA species 
(exon skipping, intron inclusion, and cryptic site use). Veridical is 
designed to be used with large data sets, as the statistical analysis 
gains power with increasing numbers of control samples. A recent 
study of 442 breast cancer tumors from the Cancer Genome Atlas 
Project revealed 5,206 putative splicing mutations using the Shan-
non Pipeline. Veridical was then used to confirm exon skipping, 
leaky or cryptic splicing of 988 of these variants47. Veridical is also 
available through the same interface as the above mentioned tools 
(www.mutationforecaster.com).
Natural sites
The early splice site recognition literature often over simplified the 
composition of the U1/U2-type 5´ donor and 3´ acceptor sites by 
presenting only consensus sequences and truncating the positions 
in each site16,48,49. However, the conserved tracts extend well beyond 
the canonical GT and AG dinucleotides adjacent to intron/exon junc-
tions. Furthermore, a small, albeit significant, proportion of natural 
donor sites (~800, or 0.7%) contain cytosine at position +2 in the 
genome. This is reflected by a corresponding small decrease in aver-
age information at this position (Figure 1). Sequences adjacent to 
these positions are more variable, but are nevertheless essential for 
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the accurate recognition by the spliceosome. Specifically, the donor 
site is defined by the three terminal nucleotides of each exon and 
the first seven bases of the downstream intron. Conversely, acceptor 
sites are represented by the first two bases of the exon, and the last 
26 bases of the upstream intron. Because ASSA and ASSEDA use 
an integer-based coordinate system, there is a zero coordinate at the 
first intronic base of each splice site (Figure 1), which is not used in 
the conventional numbering system. The coordinate ranges for the 
donor and acceptor site positions are therefore [-3, +6] and [-25, +2], 
respectively. Individual information analysis computes the Ri values 
over these intervals for normal and variant-containing splice sites. 
As discussed below, information content present in intronic inter-
vals justifies sequencing and analysis of sequences well beyond the 
locations of the splice junctions themselves.
Certain variants within donor and acceptor sites are tolerated and 
may even have benign effects, while others have a deleterious 
impact on spliceosomal recognition. IT accounts for all of these 
possible outcomes. Unusual donor sites (i.e. with cytosine at posi-
tion +2) are detected by information analysis, but could be falsely 
called deleterious by consensus sequence-based methods. Although 
the terminal position of exons contributes significantly to donor 
splice sites with a preference for G, a significant proportion of sites 
naturally possess A or U at this position, or less frequently, C.
Of the published IT-based variant analyses, single nucleotide 
variants (SNVs) that were reported to affect a natural splice site 
(multi-nucleotide and insertion/deletion variants are listed sepa-
rately in Supplementary Table 3) were compiled and reanalyzed. 
After reducing this set to only those variants occurring within the 
intervals covered by the splice site information weight matrices 
described above, 1120 SNVs were reported to affect the strengths 
of either natural donor or acceptor sites. A variant was considered 
deleterious if it was predicted to affect splicing (either leaky expres-
sion or exon skipping), or if it was experimentally shown to reduce 
or abolish splicing of the corresponding exon. In instances where 
prediction and validation did not concur, the latter were used to 
determine the effect of the variant. Variants predicted to have a 
neutral effect but demonstrated to be deleterious in the validation 
study were classified as damaging. In total, 1036 deleterious natural 
splice site variants were analyzed (Supplementary Table 4).
Sequence conservation has long been considered a surrogate 
measure of evolutionary constraint and, by inference, functional 
significance. The average information quantitates the relative con-
servation at each of the positions within a binding site. We compiled 
the mutation spectra for all mutations that significantly affected the 
strengths of donor and acceptor splice sites and compared these 
with the average information contents at each position. Figure 1b 
indicates, at each position of the natural acceptor and donor sites 
the frequencies of variants deemed deleterious by information 
analysis. Interestingly, when the sequence logo is overlaid with 
the histogram of the corresponding mutation spectra, the relative 
frequencies of deleterious mutations and the average information 
are comparable. Indeed, these frequencies and the information 
contents across each type of site are strongly correlated (r = 0.95 
for acceptors and 0.90 for donors). Our interpretation is that the 
susceptibility to deleterious mutation at a position is related to its 
overall conservation within the splice site, which reflects the contri-
bution of that ribonucleotide to the stability of the interaction with 
the corresponding spliceosome. Nevertheless, there is an unstated 
bias in ascertainment in these mutation spectra. Variants occurring 
at sites with low information and/or that are benign are under rep-
resented, as they are less likely to be associated with genetic dis-
ease, and were less likely to be reported. Also, the distribution is 
dependent on the region sequenced by the authors of the reviewed 
publications; in early work, the full sequence interval containing 
the entire splice site was sometimes not included or unavailable 
for analysis.
An interactive website was created to summarize this set of SNVs. 
This software application renders interpretations of variant effects 
in a more practical, useful way than the corresponding table of sup-
plemental data (Supplemental Table 5). The “Splicing Mutation Cal-
culator” (SMC; http://splicemc.cytognomix.com) is a web service 
that amalgamates all published results for the same type of substi-
tution in a natural splice site, regardless of genic context. Variants 
that create cryptic splice sites that do not alter the strength or have 
a marginal effect on the natural site were excluded. We consider 
these cases to be sequence-specific as opposed to positional. With 
this program, users have the option of exploring mutation data (at 
present, only SNVs can be analyzed) linked to the original litera-
ture citations. SMC processes and provides literature support for the 
variants that occur within the defined regions spanned by natural 
splice sites. The user first selects the type of site (donor or accep-
tor), position (based on ASSEDA’s integer-based system), wild-type 
or reference nucleotide, and the alternate substitution at that posi-
tion (Figure 2a). The software tool outputs the ΔRi and the number 
of variants that have been reported and analyzed to date using IT 
(Figure 2b). SMC provisionally classifies the reported variants 
based on the degree to which these predicted effects are expected to 
decrease spliceosomal affinity, and consequently splicing. The fol-
lowing criteria are empirically based on affinity changes and a sum-
mary of published phenotypes associated with these changes: “Del-
eterious” (if the site is weakened by more than 7.0 bits), “Probably 
Deleterious” (if the site is weakened such that -4.0 bits ≥ ΔRi ≥ -7.0 
bits), “Leaky” (the site is weakened such that -1.0 bits ≥ ΔRi ≥ -4.0 
bits), or “Benign, probable polymorphism” (if the site is weakened 
by less than 1.0 bits). The “Benign” variants, which are likely poly-
morphisms are now catalogued (See Supplementary Table 6 for the 
list of benign variants that were added). It is important to appreciate 
that the ΔRi is a constant for a specific nucleotide change at a specific 
position, though the absolute strength of the splice site depends on 
the sequence context of the mutation. This context varies between 
mutations, and Ri,initial is not the same for each case, which can result 
in different Ri,final values for different mutations.
Besides published sources, the software can also predict effects 
of mutations by computing ΔRi values directly. Particular substi-
tutions that have not been reported in Supplemental Table 5 can 
nonetheless be provisionally interpreted. The ΔRi value is computed 
and reported from the ribl. While SMC enables rapid exploration 
of results for validated and novel mutations, it is, however, not a 
replacement for ASSEDA or the Shannon Pipeline, since it does not 
consider the sequence context, which can also influence the inter-
pretation of deleterious, leaky, or benign variants.
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Minimum splice site information content and exceptions
The minimum theoretical information content of a binding site, 
Ri,min, is zero bits21. Comparison of the Ri, values of a series of inac-
tivated and minimally active splice sites revealed the minimum 
strength of functional splice sites (Ri,min) to be at least 2.4 bits for 
the original donor and acceptor models of Stephens and Schneider 
(1992) (based on 103 mutations with functional validation, includ-
ing 57 natural and 46 cryptic site activating mutations)25. This value 
was redefined based on information models from a genome-wide 
set of donor and acceptor models (Figure 1a) to be 1.6 bits using the 
identical set of mutations33. It is likely that the differences between 
these values are not significant and are attributable to the increased 
precision of the ribl using the ~50-fold larger set of sites. Weakened 
natural sites, with significantly reduced Ri values that remain above 
these thresholds, are considered to be leaky (lower affinity bind-
ing), whereas those below this threshold are found to completely 
abolish natural splice site recognition, resulting in either exon skip-
ping or activation of neighbouring cryptic splice sites. However, 
these outcomes are not mutually exclusive, since leaky splice site 
mutations may also result in exon skipping and/or activate neigh-
bouring cryptic sites. Natural splice sites below these thresholds 
are extremely rare, and their recognition is likely enhanced through 
the binding of specific RNA binding proteins that promote exon 
definition (eg. XPC exon 4 acceptor and MYBPC3 exon 12 accep-
tor, genes involved in xeroderma pigmentosum and hypertrophic 
cardiomyopathy, respectively50,51).
Figure 2. Sample  retrieval  of  average change  in  information content  (ΔRi) with  splicing mutation calculator  (SMC)  for published 
mutations. A) Example mutation input for SMC (T>A at the 3rd intronic position of natural acceptor). The type of splice site is selected by 
clicking on the corresponding sequence logo (acceptor [left] or donor [right]). The purple slider bar appearing below the logo is used to 
select the position of the mutation. The reference and mutant nucleotides are then designated, and the variant is submitted to the software 
(‘Submit your selection’). SMC outputs a table indicating the user input, the number of instances in the literature where this substitution has 
been analyzed using IT, and the computed ΔRi values (in bits) using both the old (1992; top) and new (2003; bottom) ribls. The cell colour 
for ΔRi values indicates the predicted severity of the inputted variant according to defined thresholds25,157. B) Tabular output detailing each 
instance of the selected mutation from the source table. The user may view, in a separate window, extensive details of all variants referred 
to in SMC output (Supplementary Table 5).
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Leaky natural sites have Ri values exceeding the Ri,min threshold, 
which, in theory, retain some capacity to be recognized by the spli-
ceosome. There were 84 variants predicted to cause leaky splicing, 
of which 19 were shown experimentally to lead to exon skipping 
without any detectable residual natural splicing (Supplementary 
Table 2: #32, 120, 128/380, 195, 276.5, 355, 360, 363, 364, 365, 
379, 409, 477/496/934, 573, 842, 853, 883/1589, 886, and 918). 
Of those, seven are donor splice site mutations at position +5 (ΔRi ~ 
-3.5 bits; #128/380, 195, 355, 842, 853, 883/1589, 886), four alter 
the first exonic nucleotide of a donor site (ΔRi ~ -3.0 bits; #276.5, 
360, 379, 409), and three are donor mutations at position +4 (ΔRi ~ 
-2.6 bits; #120, 365, 573). The Ri,final values of these 19 inactivated 
natural sites range from 2.7 to 8.8 bits, which suggests the possibil-
ity that the variant may also simultaneously affect other adjacent 
or overlapping sites that preclude recognition of the mutated natu-
ral site. Additionally, weakening of 11 of these variants activates 
a neighbouring cryptic splice site, in which no residual natural 
splicing was detected. However, changes in splice site preference 
due to small changes in binding affinity within exons are probably 
related to the processive nature of donor splice site selection52.
Leaky splicing mutations are readily detected when the expressed 
transcript contains the causative variant or a neighbouring polymor-
phism. However, there are a number of practical limitations on the 
methods for experimental validation of leaky splicing mutations. 
RT-PCR alone would only be considered reliable for confirmation 
of homozygous mutations (and in one case, a compound hetero-
zygote where two separate variants abolished natural splicing of 
the same exon), unless combined with a secondary quantitative 
methodology53. Similarly, it is difficult to assess leaky splicing of 
heterozygotes using RNAseq data, as reduced levels of wild-type 
splicing are challenging to determine without adequate read cover-
age and controls for comparison. However, leaky splicing can be 
assessed by comparing the frequency of the causative allele to the 
normal allele in the same cell line when the variant is present within 
the sequenced reads44. These are special cases however, as the vari-
ant itself must either be expressed within an exon or, if intronic, 
must lead to an activation of a cryptic site further into the corre-
sponding intron.
We previously suggested that weaker splice sites are more suscep-
tible to mutational inactivation relative to stronger sites25. In the 
present study, all experimentally verified variants affecting natural 
sites (where leaky and abolished splicing could be differentiated) 
were analyzed (N = 98). Variants predicted to abolish splicing 
(Ri,final < Ri,min and/or ΔRi < 7.0 bits) were filtered out, as large changes 
in binding affinity will essentially abolish splicing, despite remain-
ing binding strength and regardless of initial Ri value. Supplementary 
Figure 1 illustrates the frequency of inactivation by these variants 
relative to initial Ri value. Variants occurring at weak splice sites 
(Ri,initial < 4 bits) abolish splicing in 5 of 6 cases (where ΔRi < 7.0 
bits), but are not represented as they all weaken the site below Ri,min. 
The remaining variant slightly weakens a site where Ri,initial is -0.1 
bits (where ΔRi = 0.5 bits), and its recognition may be supported 
by SR elements50. Moderate strength splice sites (5.0–11.0 bits are 
inactivated in 25–60% of cases), and mutations at strong splice sites 
(Ri,initial ≥ 12 bits) tend to be leaky (Supplementary Figure 1b).
Mutations that abolish natural sites (without cryptic splice site acti-
vation) are expected to result in a complete loss of normal splicing. 
However, of the 94 variants that reduced natural splice site strength 
below Ri,min, 11 were reported to have residual normal splicing activ-
ity (Supplementary Table 2: #185/750, 275, 881, 914, 1315, 1321, 
1325, 1326, 1361, 1380, and 1407)25,44,54,55. Two of these occurred at 
the G of the +1 position of the donor site (Supplementary Table 2: 
#185/750 and 1326), which is essentially invariant in functional 
splice sites. This suggests potential problems in IT or experimen-
tal analysis of these mutations. Surprisingly, the majority of these 
variants occur at the +2 position of a donor splice site and are 
T>G mutations, which are predicted to abolish splicing activity44. 
However, the analysis of RNAseq data for these variants showed no 
splicing defects (Supplementary Table 2: #1315, 1321, 1325, 1361, 
1380 and 1407). One explanation is that resultant aberrantly spliced 
transcripts were subjected to nonsense-mediated decay (NMD) and 
degraded. Another possibility is that the coverage of these splice 
junctions is insufficient to distinguish expression of a single allele 
from that same allele plus the leaky splice junction. The remaining 
variants differ in the position within the splice site and decrease 
natural site strengths to between 0.9 to 2.2 bits25,54.
Theoretically, a site lacking the canonical G at +1 (donor) or -1 
(acceptor) position of a natural site may exceed Ri,min. Ozaltin et al. 
(2011) and Di Leo et al. (2009) each assessed mutations at positions 
+1 or -1, which weaken natural splice sites to Ri > Ri,min, and note 
that these sites are predicted to be leaky56,57. However, this is not the 
sole criterion for interpreting splice site mutations using IT-based 
methods. The overall change in binding affinity must also be con-
sidered, as both mutated sites were predicted to have only 0.4–0.5% 
of the binding affinity of the corresponding natural splice sites56,57.
Branch-point mutations
Although branch-point site (BPS) recognition occurs independently 
and post-exon definition, mutations in this sequence have also been 
described, due to its proximity to the natural acceptor site. Fol-
lowing the recognition of and binding to the 5´ss (upstream donor 
site) by the U1 snRNP, the U2 is recruited to the 3´ss (downstream 
acceptor) and recognizes the BPS, resulting in the formation of the 
pre-spliceosome58. Association of U2 with the BPS is essential, as 
it is the first energy-requiring step, allowing for the tri-snRNP com-
plex of U4/U6 × U5 to be recruited to the BPS, which produces 
a catalytically active spliceosome59. The BPS typically contains a 
conserved adenosine and a downstream polypyrimidine tract. It is 
located within 40 nt of the natural 3´ss, however there are reported 
cases where it can be up to 400 nt away.
Recognition of the BPS is thus a crucial step in proper splicing, and 
sequence variants can disrupt this event, impede lariat formation, 
and intron excision. The complete list of BPS variants analyzed 
using the ASSA and ASSEDA server can be found in Supplemen-
tary Table 7. The variants range in distance from 0–76 nt from the 
natural acceptor junction, and either weaken, abolish or strengthen 
the BPS. When validation assays were performed, the prediction 
by the server was correct in 9/11 cases. We deemed the two other 
cases to be partially discordant (NM_004628:c.413-24A>G and 
NM_005902:IVS8-55A>G). ASSEDA predicted these variants to 
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abolish the BPS, but leaky and normal splicing were observed, 
respectively. The predictions are partially concordant with experi-
mental findings because ASSEDA also predicted the existence 
of nearby alternative BPS, which if used, could account for the 
observed phenotype.
Although IT-based prediction of a variant effects on BPS has been 
accurate, the number of validated sites used to compute the ribl is 
substantially smaller (N = 20), and it is not as reliable as those used to 
determine Ri values of natural acceptor and donor sites. Furthermore, 
these motifs are short and relatively frequent in unspliced mRNA. 
One possible explanation for the rarity of BPS mutations is that com-
pensatory, alternative BPS sequences can be recognized and used. 
Furthermore, the weak constraint on the precision of the distance 
between the BPS and the 3´ (acceptor) splice site (Figure 3) further 
enables activation of these alternative sites. These factors increase 
the chance that a variant will be falsely predicted to affect a BPS. For 
example, variants within donor splice site sequences are routinely 
predicted to alter strength of false BPS. This error is easily avoidable 
if the potential recognition sequence is filtered for the genomic con-
text of the variant, as well as its proximity to acceptor splice sites.
have long been recognized, IT analysis correctly predicts most, 
but not all, cases (Figure 4). The challenges in identifying poten-
tial cryptic sites or determining activation are attributable to our 
incomplete understanding of the requirements for activation63–65, 
which include exon length, processivity of donor site recognition, 
and involvement of splicing regulatory factors. A database of aber-
rant 3´ and 5´ splice sites has been compiled65.
Another bioinformatics method for cryptic site recognition relies 
on a training set composed of cryptic sites that are known to be 
used66. There are a number of drawbacks to this approach: the train-
ing set is itself not representative of all cryptic sites; and sites that 
are altered but unused cannot be discriminated from those that are 
activated (since the latter group also depends on the strength of the 
corresponding natural splice site). IT-based methods rank cryptic 
and cognate natural site strength in a way that predicts whether the 
site will be activated, as well as the abundance of each pair of splice 
isoforms. Furthermore, the structures of the prospective isoforms 
are presented by ASSEDA with relative quantitation of each, both 
prior to and post-mutation.
During our review, we noted 203 variants with experimental sup-
port for cryptic splicing (Supplementary Tables 8–10). Of these, 
38 variants resulted in Type 1 cryptic splicing. From those, site 
activation (existence of the site and strength ≥ 2.4 bits25) was cor-
rectly predicted by ASSEDA in 34 cases (89.5%). We identified 
56 variants resulting in Type 2 splicing, 38 of which (67.7%) were 
accurately predicted, while the remaining 119 variants resulted in 
Type 3 cryptic splicing and 99 (90.8%) of the alternate splice sites 
matched predictions.
Prediction of Type 3 cryptic splicing was more accurate than Types 
1 or 2. The criteria for concordance with experimental data were 
that ASSEDA predicted both the cryptic site and that the variant 
weakened the natural site. However, the strength of a site is not 
the sole determinant of whether or not a site is activated. Unlike 
natural sites, novel cryptic sites are not under selection to maintain 
binding to the spliceosome, and their genomic context is less con-
strained than natural splice sites. The presence of cooperative splic-
ing enhancer or repressor elements adjacent to cryptic sites, which 
could influence cryptic splice site activation, is not yet predictable. 
Additionally, many of the reported activated cryptic sites have been 
confirmed using non-quantitative approaches, and these may not 
constitute the predominant splice forms relative to constitutive 
exons with stronger natural sites. Finally, certain isoforms may not 
be detected; as aberrant transcripts are often subject to degradation 
and the tools used to evaluate functional splicing consequences do 
not always have sufficient resolution to distinguish small differences 
in isoform structure. All of these factors can affect the concordance 
of predicted cryptic site activation with experimental validation.
We also separated each sub-group of cryptic splice variants by loca-
tion (intronic vs. exonic) and computed the average difference in 
strength between pairs of natural (post-mutation) and the activated 
cryptic sites. For intronic Type 1 variants, activated cryptic sites 
were 0.9 ± 5.3 bits stronger than the corresponding natural site 
(N = 12). There were eight Type 1 variants (4 at acceptors and 4 
at donors) that were missed, because the Ri,final value of the natural 
Figure  3.  Ri(b,l)  matrix  used  for  the  prediction  of  a  variant’s 
effect on branch-point sites. Sequence logo for information model 
for the branch-point site, created using 20 annotated branch-point 
sequences.
Activation of cryptic splicing
It has been estimated that 1.6% of disease causing missense muta-
tions can affect splicing and recent predictions suggest that approxi-
mately 7% of exonic variants in the general population may disrupt 
splicing, which includes cryptic splicing60,61. The genome is replete 
with pseudo (or decoy) splice sites with varying degrees of similar-
ity to natural sites that are not recognized in constitutive splicing62. 
However, mutations that alter the strengths of either these decoys 
or the natural splice site of the same polarity may shift the balance 
of isoforms towards non-constitutive splice isoforms that predomi-
nate over or eliminate normal mRNAs (Figure 4). Mutations can 
create a cryptic splicing event by creating or strengthening a site 
in either intronic or exonic regions (Figure 4, Type 1), weaken the 
natural site while simultaneously altering an overlapping decoy site 
(Figure 4, Type 2), or exclusively weaken the natural site, leading 
to the activation of a pre-existing decoy site (Figure 4, Type 3). 
Although the contributions of cryptic splicing to genetic disease 
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site exceeded the strength of the corresponding cryptic site by ≥ 1.0 
bits (variants with ΔRi < 1.0 bits are not reliably detected experi-
mentally). We hypothesize that these cases could be explained 
by concomitant changes in surrounding regulatory binding site 
sequences. Exonic Type 1 variants were often slightly weaker than 
their cognate natural sites (-1.1 ± 3.8 bits; N = 26). Nearly all of 
these involved ectopic donor site activation (12 of 13), consistent 
with a processive mechanism for donor site recognition, which 
searches downstream from the acceptor splice site to the first donor 
site of sufficient strength to form an exon38. The opposite pattern 
was observed with intronic Type 2 cases, in which 20 of 21 excep-
tions occurred at acceptor sites. On average, the activated cryptic 
site exceeded the strength of the cognate natural site (1.4 ± 4.6 bits; 
N = 57). Activated, exonic Type 2 acceptor cryptic sites tended 
to be weaker than their natural site counterparts (-2.3 ± 3.4 bits; 
N = 4). This result may be attributable to a low sample size, with 2 
of these mutations exhibiting natural sites that were stronger (≥ 1.0 
bits) than the corresponding cryptic site (1 donor and 1 acceptor). 
Finally, Type 3 activated intronic cryptic sites exhibited the greatest 
difference between the strengths of cryptic sites and cognate natural 
splice sites (6.3 ± 4.9 bits; N = 104). This category contained the 
fewest number of exceptional cryptic sites, with Ri values less than 
those of natural sites (5 acceptors and 3 donors). This is consistent 
with the idea that the intronic cryptic sites are generally not under 
selection for adjacent functional regulatory binding sites, and, in 
order to be activated, are required to be substantially stronger than 
the natural site. Although Ri,final values were stronger (2.1 ± 1.9 bits; 
N = 20) than the natural site, exonic Type 3 cryptic splice sites did 
not show as great a difference in strength with a single exceptional 
case (of an acceptor). Despite these exceptions, activated cryptic 
splice sites are generally stronger than the corresponding natural 
splice sites25.
The distribution of activated cryptic sites relative to their natural 
splice site is indicated in Figure 5. Among the reported muta-
tions, donor or acceptor cryptic sites are activated with similar fre-
quencies (113 donors and 108 acceptors). These cryptic sites are 
located within both introns and exons (59.3% of cryptic donors 
and 38.0% of acceptors are intronic, the remainder are exonic). 
Cryptic sites have been confirmed to occur over a broad range of 
Figure  4.  Outcomes  of  cryptic  splicing mutations. A prototypical internal exon (in purple) with flanking exons (in blue); introns are 
represented by black solid, and dashed lines (top). The three types of cryptic splice site activation are then illustrated. Type 1 cryptic splice 
site activation (left) is caused by the activation (green arrow) of a cryptic site by strengthening a pre-existing site, or by creating a novel splice 
site (blue). Type 2 (middle) results from the simultaneous weakening or abolition (red arrow) of the natural splice site while strengthening or 
creating (green arrow) a cryptic site. Type 3 (right) involves the activation of a pre-existing cryptic site due to the weakening or abolition of 
the natural splice site (indicated by orange triangle). The number of cases that have been reported in the literature that has been analyzed 
by IT for each type is indicated, with the percent accuracy in parentheses. The bottom row represents the resulting mRNA structure due to 
the activated cryptic splice site.
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distances from corresponding natural sites, however there is a dis-
tinct preference for cryptic site activation adjacent to the accep-
tor intron-exon junction. These splice sites are most common at 
the first nucleotide downstream from the natural acceptor splice 
junction (Figure 1), which has particular implications for the 
approaches used to verify the structure of the aberrant transcript 
(See Validation methods).
Combinatorial effects
While functional natural splice sites and an intact BPS are integral 
for accurate and efficient splicing, other genetic elements have been 
shown to make essential contributions to exon definition67. Introns 
will often contain more than one potential splice site recognition 
sequence, but nevertheless, the correct natural site is consistently 
selected62. Differences among the strengths of potential sites, as 
determined by IT analysis, are a major, but not the sole, determi-
nant of splice site utilization. The implication is that additional 
sequences within the gene are necessary to ensure specificity and 
precision of exon recognition. Studies of facultatively expressed 
alternative exon structures have revealed cis-acting sequence ele-
ments that function to enhance or repress exon recognition. These 
sequences cooperate with factors that recognize natural splice 
sites, whose sequences and relative strengths can vary consider-
ably. Depending on their context, these elements have been referred 
to as exonic splicing enhancers (ESEs), exonic splicing silencers 
(ESSs), intronic splicing enhancers (ISEs) or intronic splicing 
silencers (ISSs). In general, these elements serve as binding sites 
for trans-acting elements, which will either promote or impede the 
spliceosomal recognition of a splice site. The majority of enhancer 
elements will act through the recruitment of SR proteins and asso-
ciate components of the U1 and U2 spliceosomes68,69. Silencers are 
often of the hnRNP class, which act through a diversity of mecha-
nisms including steric hindrance, the formation of dysfunctional 
complexes, or blocking processiveness70–72. To add to the complex-
ity of splicing regulation, it has recently been shown that SR protein 
function is dependent on context, i.e. whether the corresponding 
binding site is intronic or exonic73,74.
To improve accuracy of exon definition, the strengths of regulatory 
elements (i.e. their Ri values) have been incorporated into splicing 
mutation prediction. The significance of regulatory elements in dis-
ease has been demonstrated in many cases. For example, in the NF1 
gene, ESE disruption is the primary cause of exon skipping75. Many 
other genes [Adenomatous polyposis coli (APC), survival motor 
neuron (SMN), bestrophin 1 (BEST1), pyruvate dehydrogenase 
alpha 1 (PDHA1)]76–79 have been proven to harbour variants that 
disrupt ESEs and have a confirmed impact on mRNA splicing.
Adding to the complexity, the recognition sequences for these RNA 
binding factors, while well defined, tend to be short, and can vary 
to the degree that the same sequence may contain overlapping ele-
ments of binding sites for multiple factors. However, this does not 
necessarily imply that such a sequence is bound with similar affin-
ity by each factor or that it contributes to exon definition. At the 
same time, these sequences tend to be evolutionarily conserved and 
may be required for proper splicing80,81.
Figure 5. Distribution of activated cryptic sites. The frequency of validated cryptic splice acceptors (A) and donors (B) occurring at 
positions relative to the natural splice site. Positions are given using ASSEDA coordinates. Lower two panels magnifies the cryptic site 
distribution of the region circumscribing the natural splice site.
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ASSEDA optionally incorporates PWMs for regulatory bind-
ing sites for mutation analysis (Table 1) in addition to the default 
donor and acceptor sites. The program selects the most proximate 
predicted ESE/ISS to the natural splice site when calculating Ri,total. 
The molecular phenotype, which dictates the splice isoforms (and 
their relative abundance) that are predicted, accounts for both the 
potential effect on the natural site and the most relevant splicing 
regulatory site. For these regulatory binding sites, a second gap sur-
prisal term specific to the ESE/ISS of interest is applied to the Ri,total 
calculation38. The gap surprisal functions for SF2/ASF and SC35 
have been previously described38, where the most common distance 
of the ESE/ISS is within 10 nt of the natural site. The gap surprisal 
penalty gradually increases with distance from the natural site. 
Gap surprisal distributions for ELAVL1, TIA1 and SRp55 show a 
similar pattern, while hnRNPA1 and PTB binding sites are strongly 
clustered around splice junctions. It should be feasible to include 
the contributions of multiple splicing regulatory binding sites of 
the same or different RNA binding proteins in determining Ri,total; 
however this capability had not yet been implemented. Currently, if 
multiple sites of the same type are altered, the strongest (before or 
after mutation) is chosen by ASSEDA software.
Although the disruption of splicing regulatory sequences can cause 
aberrant splicing, the interpretation of variants affecting these sites 
is not as straightforward. Due to their degenerate nature, short 
sequence, and a lack of understanding of the context of their use, 
altered regulatory sites should be functionally validated before 
being deemed pathogenic10. Using variants from a number of dif-
ferent studies, ASSEDA accurately predicted experimentally deter-
mined changes in binding at a splicing regulatory site 75% of the 
time (N = 12)38. However, there were instances where regulatory 
sequences had been analyzed by IT, and considered to contribute 
to disease, but the results were not reproducible. For example, 
Kölsch et al. (2009) described SNPs associated with Alzheimer’s 
Disease, one of which strengthened and created SRp40 and SRp55 
sites, respectively, but were reported by authors to be abolished97. 
This study did not report any evidence to support the significance 
of these predictions.
Functional validation of the effects of these mutations could 
contribute to understanding the roles of these factors in regulating 
constitutive splicing. Similarly, there is still little understanding 
on how multiple regulatory binding sites within the same region 
function as a unit. Using a pull-down assay, Olsen et al. (2014) 
demonstrated how different variants affect the binding of multiple 
regulatory proteins26. One mutation was predicted to create and 
strengthen multiple hnRNPA1 sites and slightly strengthen an SF2/
ASF (SRSF1) site. The pull-down studies showed up-regulation of 
hnRNPA1 binding and a decrease in SF2/ASF binding. However, 
SF2/ASF binding increased when a mutation disrupting hnRNPA1 
affinity was introduced, suggesting that the strong hnRNPA1 sites 
out-compete the weaker SF2/ASF site.
In some instances, alterations in regulatory splice site recognition 
sequence and natural splice strength occurred concomitantly, with 
both predicted to have similar effects on splicing. Alteration of a 
regulatory sequence can sometimes provide a plausible explana-
tion for discordant in silico prediction and experimental validation. 
As an example, Smaoui et al. (2004) analyzed a donor site muta-
tion (NM_001040667:c.1327+4A>G) in HSF4 in a family with 
congenital cataracts53. This variant was predicted to cause 
leaky splicing (Ri,final = 5.4 bits; ΔRi = -2.6 bits; 67.5% residual 
binding), however RT-PCR showed complete exon skipping. 
Our further analysis showed that it is predicted to also create 
an overlapping hnRNPA1 site (Ri,final = 4.2 bits; ΔRi = 17.1 bits). 
Another case involved a mutation in the XPC gene (NM_004628:
c.2033+2T>G) that created a novel intronic cryptic site 4 nt 
downstream of a natural donor site98. However, a weaker site 68 nt 
downstream from the natural site was activated. A possible expla-
nation could be that activation of the cryptic site is influenced by a 
neighbouring hnRNPA1 site that is itself strengthened (Ri,final = 5.2 
bits; ΔRi = 2.2 bits) and an SRp55 site that is significantly weak-
ened (Ri,final = 1.9 bits; ΔRi = -4.0 bits).
The effects of changes in regulatory binding site strengths may ascribe 
potential functions to previous VUS. For example, Maruszak et al. 
(2009) present a PIN1 variant associated with late-onset Alzheimer’s 
Disease (NM_006221:c.58+64C>T)99. Based on IT, it is expected 
to abolish an intronic SC35 site, which could have either an enhanc-
ing or silencing effect (Table 1). A 2.82-fold decrease in transcript 
levels was demonstrated, which is concordant with previous find-
ings reporting decreased PIN1 levels in the brains of patients with 
Alzheimer’s Disease. Another study described an exonic missense 
variant within the ETFDH gene in a patient with multiple acyl-CoA 
dehydrogenase deficiency (NM_004453:c.158A>G) that showed evi-
dence of exon skipping. The variant was predicted to be “benign” 
or “tolerated” when evaluated with PolyPhen and SIFT26. ASSEDA, 
on the other hand, predicted the creation of an hnRNPA1 site 
(Ri,final = 5.9 bits; ΔRi = 17.1 bits), a slightly strengthened hnRNPH 
site (Ri,final = 4.0 bits; ΔRi = 0.2 bits), the abolition of an SRp40 site 
(Ri,final = -3.3 bits; ΔRi = -6.3 bits) and two novel, weak SF2/ASF 
sites (Ri,final = -4.6 bits; ΔRi = 0.8 bits and Ri,final = -2.4 bits; ΔRi = 0.4 
bits)26. The natural donor site was unaltered by the mutation. As 
indicated earlier, the mutation was confirmed experimentally to 
increase hnRNPH and hnRNPA1 and decrease SRp40 and SF2/
ASF binding.
Validation of results
A number of early mutation studies did not perform expression anal-
ysis and relied solely on the ASSEDA or ASSA server to interpret 
potential mutations. This is not recommended, as there are limita-
tions to any in silico predictive method, which impacts accuracy 
and precision of the prediction. Assuming that the impact of the 
mutation on expression can be detected, experimental validation of 
IT-based mutation analysis can reveal its limitations. We describe 
the various validation methods that were employed in the articles 
where expression data were available. Below, advantages and dis-
advantages of these approaches are explored, as well a show lower 
sensitivity validation can result in misinterpretation. Finally, we 
determine the accuracy of IT-based prediction, and point out some 
instructive, discordant cases.
Validation methods
The two most widely used methods for validating mutant mRNA 
splicing isoforms have been RT-PCR analysis of patient mRNA, and 
transfection of minigene constructs expressing the mutated exon into 
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Table 1. Splicing regulatory protein binding sites ASSEDA scans for and their associated effect on splicing.
Splicing Factor Rsequence (bits) Sequence Logo
Location-dependent effect on 
splicing
Intronic Exonic
hnRNPH 8.9 ± 1.8 E82,83 / S84,85 S / E86
hnRNPA1i 4.6 ± 1.5 S / E87 S 
TIA1 7.6 ± 3.1 E N/A
SRSF6 (SRp55) 5.2 ± 1.4 E / S85 E / S
SRSF5 (SRp40) 4.5 ± 1.5 E / S85 E / S88
SRSF2 (SC35) 4.5 ± 1.6 E / S89 E / S90
SRSF1 (SF2/ASF)91 5.8 ± 1.5 E / S89,92,93 E / S
PTBii 4.9 ± 1.9 S / E94 S 
ELAV1 9.6 ± 3.4 S / E / N95,96 S 
Reported dominant effect is bolded. E – Enhancer; S – Silencer; N – Neutral.
iEnhancer activity by hnRNP A1 occurs at the junction87. iiPTB does not directly enhance splicing, but can do so indirectly by 
preventing the binding of splicing repressors94.
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cell lines, followed by RT-PCR. These assays were, in some cases, 
accompanied by other techniques such as direct sequencing of 
cDNA, Western blotting, luciferase expression assays or immunos-
taining. A number of studies used quantitative RT-PCR or real-time 
PCR to estimate isoform abundance. RNA or cDNA sequencing 
and exon expression microarrays were also used in several studies 
to support in silico predictions. Certain functional assays that we 
reviewed were unique to a single study, including: allelic insta-
bility, exon trapping, immunoprecipitation of splicing factors, and 
flow cytometry26,100–102. Other indirect methods of justifying the asso-
ciation between a splice site variant and disease included fundos-
copy, loss of heterozygosity, blood protein levels, and segregation 
with disease103–106. Because a variant may result in aberrant splicing 
but might not be accompanied by a detectable phenotypic change, 
we excluded the results of indirect assays of phenotype. Indirect 
measures of phenotype can support disease association, but do not 
inform about accuracy of splicing prediction.
Endpoint RT-PCR and minigene assays probe the specific variant 
in question, but do not reveal relative abundance of each isoform, 
whereas qPCR does. Neither method resolves mRNA sequence 
at the nucleotide level, which can fail to confirm predicted splic-
ing mutations, especially in instances where a small number of 
nucleotides are retained at the constitutive splice junction107. The 
resultant frameshifted mRNAs can cause premature truncation of 
the transcript (PTC), instability, and NMD, leaving no evidence 
of the mutated isoform (unless the cells had been treated with an 
NMD inhibitor). A disadvantage is that in cases where the protein 
is not degraded, but still impaired or dysfunctional, the result will 
be incorrectly categorized as benign. For example, Wessagowit 
et al. (2005) used sequencing of a COL7A1 variant (NM_000094:
c.341G>T), responsible for recessive dystrophic epidermolysis bul-
losa, to demonstrate a 87 nt deletion in the cDNA108. The authors 
also performed immunostaining of the corresponding protein with 
a monoclonal antibody, which showed no difference between wild-
type and mutant samples because the epitope was not disrupted by 
the deletion. Had the authors only performed the binding assay, the 
variant would have likely been disregarded. NMD can be a predom-
inant cause of false-negative results when validating splice variants. 
When aberrant splicing causes a frameshift and PTC, translation of 
truncated proteins is prevented, which otherwise can have dominant 
negative effects or exhibit gain-of-function109. However, if these 
transcripts are degraded and only the normal allele is detectable (in 
the case of a heterozygote or leaky splicing), then the splicing pre-
diction will not be supported. Interestingly, Khan et al. (2004) were 
able to show that NMD had occurred by comparing levels of total 
message (qPCR) between wild-type and mutant samples50. Experi-
mental methods have been developed to stabilize transcripts with 
premature termination of translation, thus circumventing NMD. 
The use of emetine, which inhibits translation and stabilizes RNA 
transcripts, can increase the relative amount of aberrant transcript 
observed110,111. However this approach can induce a stress response 
within the cell and further transcription must be halted using actino-
mycin D. This combination was used by Bloethner et al. (2008) 
in an approach called Gene Identification by NMD Inhibition112. 
Similarly, the use of puromycin and cycloheximide were shown 
to inhibit NMD and restore predicted aberrant splice forms100,113. 
Furthermore, certain mutations proximate to the penultimate exon 
evade NMD114,115.
Regulatory sequence variants
A number of assays have been developed to confirm direct effects 
of variants on splice site recognition, however fewer methods are 
available to measure effects of mutations at binding sites of splic-
ing regulatory proteins116. The most reliable approach is to associate 
a change in splicing with a change in regulatory protein binding. 
A combination of electrophoretic mobility shift assay and RT-PCR 
were used to confirm that a predicted change in an SF2/ASF bind-
ing site caused exon skipping in the CFTR gene responsible for 
cystic fibrosis117. Others performed RNA affinity purification in 
combination with Western blotting26.
Another approach tests multiple variants at the same position 
through minigene assays. Anczuków et al. (2008) observed that 
two variants at the same position in the highly penetrant hereditary 
breast/ovarian cancer gene BRCA1 (c.3600G>T and c.3600G>C) 
predicted different effects on regulatory sequences, as well as dif-
ferent observed effects on splicing118. The G>T variant was pre-
dicted to abolish a SRp40 site and weakening of an SF2/ASF site 
by both ASSA and ESEfinder, and showed a significant reduction 
in the relative amount of normal transcript. The G>C variant, which 
did not elicit a change in splicing, was not predicted by ASSA to 
have a significant effect on either site (although ESEfinder pre-
dicted weakening of the SRp40 site below its default threshold). 
The difference in splicing efficiency could be due to the loss of 
binding by one or both of these regulatory proteins. This assay asso-
ciates predicted changes to regulatory protein binding site strength 
to changes in splicing. A direct binding assay would lend key sup-
port for such predictions.
Accuracy of IT-based prediction
We previously evaluated the accuracy of IT-based prediction using 
a set of validated splicing mutations (85.2%; N = 61)28. Other stud-
ies have also evaluated the accuracy of ASSA/ASSEDA while 
evaluating differences between multiple predictive programs and 
have shown varying levels of concordance (68.8%, N = 16; 90.1%, 
N = 22; 100%, N = 24)54,107,119. With a comprehensive list of all 
published variants analyzed using IT-based methods (Supplemen-
tary Bibliography), we perform a meta-analysis of all of these vari-
ants to minimize bias in interpretation and impact of ascertainment 
of specific phenotypes from individual studies. The list of variants 
is more extensive than any previous study examining accuracy of 
IT-based methods. The variants are not restricted to a single or even 
group of diseases, but rather cover over 150 different conditions 
(see Supplementary Table 2).
In total, 905 variants were reported in 122 different publications to 
have been validated for their effects on splicing (1,727 total variants 
analyzed from 216 papers – Supplementary Table 11). In all cases, 
the authors performed information analysis; however, the validation 
experiments were sometimes contained in the original reports and 
in other cases, later studies. In a minority of mutations, the valida-
tion results were either uninformative (N = 36) or the methods did 
not directly imply an effect on splicing (N = 2); these mutations 
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were therefore excluded in determining the accuracy of predictions 
(shaded in grey in Supplementary Table 11).
More specifically, in order for experimental results and predictions 
to be considered concordant, one or more of the following criteria 
had to be met:
a. A variant predicted to abolish a splice site did abolish splic-
ing, with no residual splicing observed. Exceptions to this 
were assays in which both the mutant and wild-type alleles 
were expressed in the same cell line or patient sample, and 
could not be discriminated from one another (i.e. RT-PCR);
b. A variant predicted to be leaky exhibited residual normal 
splicing, with the exception of cases where a much stronger 
cryptic splice site was activated;
c. A variant that strengthened the natural site and showed nor-
mal or increased levels of the wild-type isoform, consistent 
with it having a benign phenotype and/or polymorphic;
d. A variant predicted to activate a pre-existing splice site, 
while also reducing the natural splice site strength, was 
demonstrated experimentally to result in cryptic splicing, 
regardless of whether it was predicted it to be the predomi-
nant isoform;
e. A variant predicted to affect a splicing regulatory protein-
binding site was consistent with validation experiments 
explicitly assessing binding affinity and associated splicing 
alterations.
Cumulatively, 87.9% of variants documented by expression studies 
(762 of 867) that satisfied these criteria were accurately predicted 
by ASSEDA. A minority of papers reported variants to be “partially 
concordant” (3.1%; 27/867), meaning that while the cryptic site 
observed was predicted, it was not the most likely splice isoform 
relative to other predicted cryptic exons. Because this method of 
scoring met our criteria (see point d above), we included these in 
our determination.
Predicted mutations discordant with validation results
Limitations of both the predictive model and the validation data/ 
methods were the primary reasons for discordance. Where information 
analysis predicted a neutral change or no effect, but validation showed 
aberrant splicing, we hypothesize that there are either unrecognized 
splicing regulatory protein binding sites that are weakened or abol-
ished, or that there are underlying mechanisms that are not currently 
addressed by current information models26,38,53–55,57,99,101,102,117,120–130. 
The validation methods used can also contribute to discordant 
results. We note that 41 discordant results originated from one of 
our own studies44. This study used RNAseq data to validate predic-
tions, a genome-wide approach that should be used with caution 
when inferring changes resulting from potential splicing muta-
tions. Until this study was published, IT-based mutation analysis 
was based on single or candidate disease gene studies. RNAseq 
reveals all changes in transcript levels for all genes, which although 
potentially relevant to splicing, may not necessarily contribute to 
the phenotype in question. This leads to the possibility, especially in 
cancer phenotypes, of bystander effects (global splicing dysregula-
tion, natural alternative splicing) that are not directly attributable to 
the predicted mutations. Furthermore, because the sequence reads 
at splice junctions are short, and often limited in number, a relevant 
splicing aberration may result from a given variant, but it was not 
detectable. Finally, the predictions of IT can pick up variants that 
should alter splicing for example, of rare recessive alleles, that may 
not have any disease relevance.
Misinterpretation of variant effects
While preparing this review, several variants misinterpreted with 
IT-based tools were noted. These variants have been re-analyzed 
to disseminate the correct findings and to avoid making similar 
errors in the analysis of newly discovered variants. Supplementary 
Table 2 contains these results. The most common problems result 
from unfounded emphases on altered or pre-existing cryptic sites 
that are determined to be significantly weaker relative to the cog-
nate natural site112,131–135, and from selectively reporting a single 
change in the Ri value when, in fact, multiple significant changes 
can be detected51,131,136–139. An example of the first type of error 
is exemplified by a variant in CGI-58 (ABDH5) in a patient with 
Dorfman-Chanarin syndrome, where the natural splice site is 9.1 bits 
(or ≥ 549-fold) stronger than the reported cryptic site132. Henneman 
et al. (2008) selectively reported the effect of a mutation that weak-
ens a natural donor splice site in APOA5 and is thought to cause 
hypertriglyceridemia, however only a change in the information 
content of an SC35 binding site was indicated139.
Other common problems include incorrect declaration of small ΔRi 
values as significant changes112,140,141, use of incorrect Ri,min values142,143, 
and the computation of predicted binding strength changes on a lin-
ear scale144 rather than the correct exponential function (i.e. ≤ 2ΔRi)21. 
Smaoui et al. (2004) described an 8.0 bit donor site as weak, which 
is actually equivalent in strength to R
sequence, the average strength36. 
Allikmets et al. (1998) and Ozaltin et al. (2011) both described an 
inactivating mutation as leaky, because the weakened site remained 
above the Ri,min56,137. However, the variant mutation produces a site 
with < 0.7% of its original binding affinity, which would substantially 
reduce exon recognition and lead to exon skipping116. Also, cryptic 
sites created in the promoter regions of genes should not be consid-
ered to be splicing mutations145. Variants that are predicted to create 
a cryptic site upstream or overlapping a natural site of the opposite 
polarity (i.e. cryptic donor upstream of a natural acceptor) have been 
reported134,135,146, which would be inconsistent with established splic-
ing mechanisms38. A rare exception that could render such a site active 
is to the creation of a cryptic exon that occurs in conjunction with 
a proximate, correctly oriented, pre-existing cryptic splice site of 
opposite polarity25,33. Insufficient numbers of examples of mutations 
creating cryptic exons have been reported to date for ASSEDA to 
accurately predict these exons by default.
Several results were generated by incorrect entry of mutations into 
ASSA/ASSEDA. For example, altered cryptic splice sites have 
been confused with natural sites51,140,147,148. Additionally, ‘residual 
binding strength’ displayed has been misinterpreted as a percent 
decrease147,149. Strong, pre-existing cryptic sites outside of the default 
sequence analysis window (54 nt circumscribing the mutation) have 
also been missed because the window was not expanded to include 
these sites150. Although the predicted isoform structure generated by 
ASSEDA will, by default, display skipping for mutated natural sites 
with Ri ≥ -7.0 bits (or ≥ 128-fold)116, smaller decreases in natural site 
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strength of an internal exon can sometimes partially induce exon 
skipping. This value is adjustable, and it may be advisable to 
explore different thresholds depending on the particular suscepti-
bility of a splice junction to exon skipping. Sharma et al. (2014) 
used the default threshold from ASSEDA to interpret CFTR muta-
tions c.2988G>A (9.6 to 6.6 bits, natural donor site of exon 18) and 
c.2657+5G>A (9.1 to 5.6 bits, natural donor site of exon 16), but 
exon skipping was documented54. IT analysis was not discordant for 
these variants, which significantly weaken the corresponding splice 
sites by ≥8- and 11-fold, respectively, and has been shown in other 
genes to lead to exon skipping, leaky splicing, or both of these out-
comes. Aissat et al. (2013) tabulated variants that were predicted to 
affect strengths of ESE binding sites, but did not comprehensively 
report all findings even though predictions by ASSA and ESEfinder 
were concordant (eg. CFTR: c.1694A>G). Alternate mutation entry 
methods, which do not use contextual gene name annotations, such as 
entry by rsID, report predicted binding changes on both strands. And 
in a study of hereditary Alzheimer’s disease, the abolition of SRp40 
binding sites on the antisense strand was confused with binding 
sites for CYP46A1, which is transcribed from the sense strand151.
Other problems include inadvertent mislabelling of splice site type 
or location152–154, interchange of the terms information content and 
change in information (Ri and ΔRi)125, and unclear variant inter-
pretation (i.e. “run on into the intron”)155. Moriwaki et al. (2009) 
claim ASSA did not predict a mutated natural donor site, but in 
fact, the site was present in our reanalysis156. Published Ri values 
from Rogan et al. (1998) and von Kodolitsch et al. (1999) are in 
some instances different from current values due to updates of the 
reference genome sequence25,157. Nevertheless, the overall predicted 
effect did not change, but initial and final Ri values were inconsist-
ent. Interpretations of certain mutations could not be reproduced 
in some instances106,148,158–160. Finally, we noted that ASSEDA can 
sometimes improperly parse indels entered using c. or IVS nota-
tion. Such errors have led to published false results70,119,161,162.
Interpretation of published variants in studies that 
use information analysis
Genotype-phenotype association
The severity of phenotype due to splicing mutations can be related 
to their effects on mRNA splicing, after careful consideration of 
the overall impact on mRNA levels and protein coding163. Signifi-
cant information changes (where ΔRi ≥ 7.0 bits or where Ri ≤ 2.4 
bits) of splicing variants in hemophilia patients (F8C and F9) were 
shown to correspond to the severe clinical phenotypes of the dis-
ease (reduced protein activity, increased clotting time, bleeding fre-
quency)130. The overall effect on the coding potential of the mutated 
transcript should be considered, as skipping events that maintain 
the reading frame commonly lead to milder phenotypes105,164,165. 
Nevertheless, two variants that abolish splice site recognition in 
PTPRO in Idiopathic Nephritic Syndrome reported by Ozaltin et al. 
(2011) had similar phenotypes even though one retained the read-
ing frame and the other caused a frameshift56. The exon deleted by 
the in-frame skipping event is highly conserved56. Exon skipping 
events that cause frameshifts close to the carboxy-terminus may 
lead to mild phenotypes, as they avoid NMD115,166. Dominant nega-
tive mutations with either Ri > Ri,min or with modest decreases in ΔRi, 
may be less likely to cause severe phenotypes, as a residual amount 
of the natural isoform continues to be expressed106,120,144,157,167–170. 
The impact of cryptic site-activating variants on phenotype can 
be similarly assessed. Activated cryptic sites which shift the read-
ing frame have been shown to be more severe clinically relative 
to those which maintain the same reading frame as the native 
gene105,108,171,172.
IT-based tools exhibit high specificity for analysis of splicing neutral 
variants in hereditary breast/ovarian cancer and other disorders119. 
These predictions can reduce the requirement for experimental vali-
dation of low-priority candidate mutations with minimal changes in 
information content17,25. IT analysis has been used in numerous stud-
ies to infer neutral effects of variants17,37,100,112,119,122,131,132,154,160,161,173–187. 
Similarly, variants that strengthen natural splice sites188–190 are also 
likely to be neutral, though these variants can increase retention 
of exons that are otherwise frequently alternatively spliced191,192. 
However, binding site variants with minimal splicing information 
changes may still alter mRNA processing by disrupting mRNA 
secondary structure193.
Polymorphisms and splicing
Early studies suggested that common polymorphic sequence vari-
ations at splice sites corresponded to small ΔRi values, consistent 
with these changes having little impact on mRNA abundance25. More 
recently, it has been appreciated that certain rare SNPs have signifi-
cant genetic loads, can actively alter mRNA splicing profiles, and 
lead to non-obvious splicing phenotypes61,191. Nevertheless, it is not 
uncommon for reports to solely analyze novel variants and ignore 
known SNPs139,160,162,194, or limit results only to those that occur in 
the vicinity of natural splice sites186. We find that 56.4% of common 
SNPs (with population frequencies ≥ 1% in Supplementary Table 2) 
within natural sites significantly alter their strength (12.8% abolish 
and 28.2% cause leaky splicing, 15.4% modestly strengthen sites 
[ΔRi < 2.6 bits]), and 43.6% have insignificant ΔRi values, as expected 
(N = 39). The mean Ri,final and ΔRi values, for these natural sites are 
7.9 ± 4.0 bits and -1.4 ± 3.0 bits, respectively, which suggests the 
effects of these polymorphisms on splicing are nil to limited. How-
ever, polymorphisms can significantly modulate splicing, as some 
common SNPs are predicted to abolish natural splicing (Supplemen-
tary Table 2: #1291, 1296, 1431, 1435, and 1436). These include 
rs10190751 in CFLAR, which modulates the production of two short 
isoforms, and is associated with an increased risk of lymphoma191,195, 
rs3892097, which alters exon inclusion in CYP2D633 and leads 
to a non-functional protein and altered drug metabolism196, and 
rs1805377 in XRCC437, which has been associated with oral can-
cer susceptibility197 and increased risk of gliomas198. There is also 
experimental support for common SNPs that have been predicted 
to affect splicing25,101,110,113,117,121,152,167,191,199. For example, experimen-
tal evidence for increased exon inclusion has been described for 
three of six SNPs that increase strength of natural splice sites191,192. 
Numerous common SNPs, which were either deemed neutral or 
predicted to affect splicing, have not been confirmed experimen-
tally17,25,28,37,55,97,102,134,136,147,148,151,154,157,168,169,181,185,187,190,200–210. Polymor-
phisms with significant information changes should be investigated, 
as they may not be completely benign and can have a significant 
impact on mRNA splicing.
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Inference of variant pathogenicity by IT analysis
Recently, American College of Medical Genetics and Genomics rec-
ommendations for reporting incidental findings in sequencing have 
suggested that bioinformatics predictions are not sufficient to declare 
clinical significance211. Preceding the publication of these guidelines, 
numerous peer-reviewed articles suggested variants analyzed by IT 
to be causative/pathogenic/disease-causing, without confirmation of 
the predicted splicing effect104,138,140,153,164,170,180,207,212–220. Other authors 
have qualified the interpretation of bioinformatic results with less 
certain terms (i.e. ‘suggest’ and ‘likely’ pathogenic)113,115,178,221–225. 
Leclerc et al. (2002) state that a predicted variant confirmed to 
affect splicing is likely deleterious, but could not be unequivocally 
shown to cause the observed phenotype169. Although IT predictions 
can relate a sequence change to the resultant phenotype, caution 
should be exercised when deeming a predicted splicing variant as 
pathogenic in the absence of other functional evidence. The high 
level of concordance between IT mutation analysis and experimen-
tal findings indicates that this approach, in conjunction with other 
evidence, can be used to detect splicing effects, which may be used 
to explain disease phenotypes.
Comparisons to other software programs
There are now over a dozen other publically available splicing pre-
diction tools, some using strategies similar (MaxEntScan [MES]) 
and others, which are quite different (NNSplice) that are com-
pared with IT226,227. Vreeswijk et al. (2009) assessed the applicabil-
ity of different splice prediction programs to diagnose BRCA1/2 
variants150. These authors recommended that the outcome of 3 
programs was sufficient for analysis, unless all three predictions 
were discordant from one another (2 for false positive predictions). 
Despite the obvious appeal of consensus between different analyti-
cal methods, a major caveat in using polling strategies for mutation 
assessment is that these approaches are prone to both systematic 
and sampling errors43.
We summarize results of 36 publications that used both IT-based 
prediction tools and one or more alternate prediction tool (14 for 5´ 
and 3´ splicing, six for splicing regulatory proteins) to assess muta-
tions26,42,100,102,106,114,117–120,126,133,135,144,150,160,162,168,169,173,181,187,191,199,212,220,228–237. 
The analysis performed by the authors allowed us to compare the 
similarity of predictions to those programs and IT in Table 2a and 
Table 2b. Those most commonly used for 5´ and 3´ splice sites 
(NNsplice, MES, NG2, HSF and SSF) were highly concordant 
for natural sites (85.4% for donor and 77.6% for acceptor sites; 
Table 2a). Discordance of acceptor predictions may be due to 
methodologies that do not analyze the complete acceptor site (HSF 
analyzes only 14 intronic nucleotides upstream of acceptor splice 
sites)238. Some programs (SSF, HSF) exhibit greater concordance 
with IT for cryptic splice site prediction (96% for donor and 76.9% 
for acceptor sites). The level of discordance between IT and other 
commonly used software programs (59.5% for donor and 60% for 
acceptor sites) may be attributable to the empirically-derived scor-
ing thresholds and the validation sets used to predict mutated splice 
sites. Models that are typically built (or trained) using known natu-
ral splice sites may be less sensitive for differentiating true cryptic 
splice forms from decoys in the genome, which tend to be weaker 
than natural splice sites. Tools are highly consistent when analyz-
ing variants expected to be neutral with respect to splicing (100%; 
N = 71). Colombo et al. (2013) compared nine programs to evalu-
ate accuracy in predicting mRNA splicing effects and reported that 
ASSA, along with HSF, demonstrated 100% informativeness and 
specificity119.
ASSEDA has also been used to analyze RNA binding proteins 
that enhance or silence exon recognition (Table 2b). ESEfinder 
was used for 42.2% of these mutations in one or more regulatory 
binding sites239,240. However, variants predicted by ESEfinder to have 
deleterious effects are discordant with some IT predictions (6 of 15; 
Table 2b). The discordance with ESEfinder may be associated with 
differences in the respective analytic methods, as several of the mod-
els (SF2/ASF, SC35, SRp40) used by ASSA and ESEfinder were 
created from the same source of experimental data90,241. While the 
majority of the discordant results were cited in a single study114 (5/6 
variants), the small size of the dataset (ranging from 28–34 sites) 
may artificially exacerbate differences between these results. In mul-
tiple instances, ASSA has been used to analyze SR proteins, but other 
programs were used to analyze 5´ and 3´ splice site mutations26,102,118. 
This was surprising, since the donor and acceptor Ri values are gen-
erated by default by ASSA and ASSEDA. The advantage of per-
forming both constitutive and regulatory splice site analysis with IT 
is that all results are reported on the same scale, and the strengths 
of all interactions, and effects of mutations are directly comparable 
to one another.
Other applications of information theory-based splice 
site analysis
The use of IT to analyze splicing is not limited to sequence variant 
analysis. The natural and alternative splicing of several genes have 
been characterized using this method110,202,242. Khan et al. (2002) 
scanned all natural sites in the XPC gene and found a weak accep-
tor (-0.1 bits), and with RT-PCR found that this exon (exon 4) was 
skipped to a greater extent than another (exon 7), which possessed 
a strong acceptor, illustrating a relationship between the infor-
mation content of a natural splice site and its level of alternative 
splicing110. IT has also been used in genetic engineering in the design 
and alteration of binding sites, and has been used in the design of 
Table 2a. Concordance of splice-prediction programs to information theory-based tools for natural and cryptic sites.
MES1  BDGP1  NG21  HSF SSF1,2  SSqF1  GS SV SP SS GenS ASD GeneS GM
Nat. Donors 42/48 37/39 24/32 23/28 25/27 15/18 6/11 9/9 5/8 2/2 1/2 1/1 1/1 -
Nat. Acc. 21/26 14/19 14/20 12/16 15/18 9/11 3/5 4/5 3/5 - - - - -
Cryp. Donors 16/24 4/8 5/10 16/17 8/8 0/7 2/2 - - - 0/1 0/1 - -
Cryp. Acc. 7/13 2/3 3/4 8/11 2/2 2/2 - - - - - - - 0/1
Neut. Mut. 31/31 8/8 4/4 26/26 - - - - - 2/2 - - - -
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constructs for transgenic animal models243–245. Thus, IT-based splice 
site analysis can be adapted for other important molecular genetic 
applications.
Guidelines for information theory-based splicing 
mutation analyses
Our comprehensive review of the use of IT in splicing mutation 
analysis has led us to propose general recommendations, which we 
formulate as guidelines. Adoption of these guidelines should ensure 
the accurate and comprehensive results from IT analyses of VUS 
and other pathogenic variants that alter mRNA splicing.
Report gene isoform and genomic coordinates
When analyzing a variant with ASSEDA, the user is prompted to 
select an mRNA isoform (GenBank or RefSeq accession) from the 
gene in question. When entering the same variant (in either IVS or 
c. notation) for different isoforms, either the variant will parse one 
but not the other representation, or the variant syntax will be proc-
essed for both. In the first situation, the user is prompted to verify the 
position and substitution, which may elicit the realization that the 
incorrect isoform had been selected. However, in the case where the 
variant can still be parsed (despite being incorrectly entered for the 
isoform selected), an incorrect nucleotide may co incidentally have 
the same sequence, and the user may not necessarily realize that the 
intended position is not being analyzed. We were unable to repro-
duce results for several variants, because the mRNA or gene isoform 
was not reported. This issue could be resolved by comparing the 
genomic sequence in papers where the context of the mutation was 
included53,98,144,181,246–248. Where flanking sequences were unavailable, 
the location of the mutation was inferred from either descriptions in 
the text, the corresponding Ri value of the splice site, or relative 
coordinate numbering147,249,250. Although we attempted to reproduce 
all the results, this was not always possible if the specified sequence 
was ambiguous or the source was deprecated (GenBank accession 
numbers, BAC clones, etc.)51,100,174,181,182,210,229,234,251,252.
We note that ASSA/ASSEDA cannot account for genes with redacted 
exons, where the exon numbering or sequence in the original 
mRNA accession has not been corrected. A well-known example 
is BRCA1, for which the constitutive isoform lacks the exon des-
ignated as number 4. IVS notation beyond this point in this gene 
must be reduced by one intron. Alternatively, one of the HGVS-
approved methods can be used to input variants, or the variant can 
be designated with the genomic coordinate (g.) format. Review of 
ASSA/ASSEDA output (coordinates and/or the sequence walker20) 
is a prudent approach to confirm that the correct region has been 
analyzed.
To eliminate ambiguity, we recommend that reported variants be 
accompanied by the accession number used in its analysis (consist-
ent with HGVS notation39) and the genomic coordinates with the 
corresponding reference genome build. The table of results from 
ASSEDA or Shannon pipeline output could also be included as 
supplementary published material. This will ensure that reported 
results can be reproduced and compared to other experimental or 
in silico results.
Report Ri values
The results generated by IT software provide Ri,initial, Ri,final, and 
ΔRi for donor and acceptor sites by default, and for all other ribl 
matrices selected. Reporting these values along with the interpre-
tation improves the clarity of said interpretation. Several publica-
tions have not reported Ri, and instead only the interpretation of 
these values128,141,149,214,229,253,254. This presumes that the analysis was 
performed correctly, and accurately interpreted. In one instance, 
our reanalysis differed from the published interpretation141. Other 
publications provide Ri values, but were incorrectly reported, which 
resulted in misinterpretations51,125. Simply reporting ΔRi itself does 
not provide sufficient information about the context of the mutation 
or possible cryptic splice sites, which is necessary to fully appreciate 
the resultant effect on splicing139,247,255. We recommend Ri values be 
provided for each variant analyzed. We also suggest that the spe-
cific donor and accept or ribl used for variant analysis be indicated, 
because of the differences obtained using the genome-wide and 
original PWMs in IT analysis33,36. The distinction can also be signifi-
cant, when the Ri,final value of a mutated splice site approaches Ri,min.
Table 2b. Concordance of splice-prediction programs to information theory-based tools for 
splicing regulatory proteins.
ESEfinder3,4  Rescue-ESE Ex Skip3,4  ESEsearch PESX
ESEs (all types) 9/15 3/4 4/14 2/3 1/1
Neut. Mut. 4/4 1/1 3/3 - -
Concordance was assessed from the analysis of variants from 36 publications which used IT-based tools and 
a secondary predictive method. Each value corresponds to the number of variants that were concordant with 
IT-based tools versus the total number of variants for each category. 1 – includes Vreeswijk et al. (2009), which 
may not have properly reported predicted cryptic sites, as they did not report any cryptic sites predicted by ASSA 
beyond the default window size (54 nt) from the mutation150. 2 – predictions made using the SSF-like algorithm 
in the Alamut splicing prediction module were combined with the SSF category (SSF is no longer supported). 
3 – Aissat et al. (2013) contributes highly to the discordance of these programs, and may be due to improper 
reporting/analysis117. 4 – Mutations predicted by alternate program to affect SR protein to which ASSEDA has no 
model (i.e. 9G8) were not included in statistics.
MES – MaxEntScan; BDGP – Splice Site Prediction by Neural Network, NNSplice; NG2 – NetGene2; HSF – Human 
Splice Finder; SSF – Splice Site Finder; SSqF – Splicing Sequences Finder; GS – GeneSplicer; SV – SpliceView; 
SP – Splice Predictor; SS – Shapiro-Senapathy; GenS – GenScan; ASD – ASD-Intron analysis; GeneS – GeneScan; 
GM – GeneMark; PESX – Putative Exonic Splicing Enhancers/Silencers.
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Consider impact of missense and synonymous mutations 
on mRNA splicing
Missense and synonymous mutations can alter natural splicing, 
create cryptic sites, and alter crucial ESE and ESS binding sites256. 
IT tools have been employed to analyze exonic variants that strength-
ened or create exonic cryptic sites, which were also confirmed 
experimentally28,42,44,46,101,108,119,127,133,152,154,180,257,258. Similarly, IT tools 
can predict potential effects on strengths of SR and hnRNP protein 
recognition sites26,120. There is no justification for cataloguing intronic 
and exonic variants, but only assessing splicing effects for the intronic 
variants or those within natural splice sites122,135,177,188,210,212,216,217,250,259,260. 
We recommend that IT-based analysis should evaluate all variants 
within a gene for potential splicing mutations.
Experimentally validate variants
Many studies have reported only coding changes and the results of 
IT (or other in silico) analyses without experimental validation. Our 
review indicated that IT-based splicing predictions are highly con-
cordant with validation results (87.9%). Nevertheless, the discord-
ant mutations support the need for robust post-prediction validation, 
since even a single discordant result can lead to misdiagnosis. We 
do not detect any consistent pattern amongst the discordant predic-
tions to provide guidance as to which IT analyses will be erroneous. 
Experimental verification will mitigate incorrect interpretations of 
IT predictions and has been recommended by others29.
Report the sequence window used in the analysis
ASSA/ASSEDA allows the user to alter size of sequence window 
range surrounding the mutation. The default window range has 
been set to maximize the speed of analysis, which is to some degree 
dictated by the number of matrices and the length of the sequence 
analyzed. Arbitrary abbreviation of the sequence analysis window 
can result in the failure to detect activated intronic or exonic cryp-
tic sites, which can in some instances significantly lengthen (eg. 
231 and 313 nucleotide extensions, respectively166,171) or shorten the 
corresponding natural exon. Therefore, we suggest expanding this 
window if one wishes to assess the possibility that long range, pre-
existing cryptic splice sites may be activated.
We note that unequivocal prediction of cryptic splice site use in 
large exons (> 1000 nt) can be challenging due to the reliance of 
these gene regions on splicing enhancers, silencers, and other regu-
latory elements to prevent ectopic splice site use and ensure fidel-
ity of splicing261. In a case of familial hypobetalipoproteinaemia, 
Di Leo et al. (2007) determined a variant abolishing the natural 
acceptor for exon 26 of APOB (7572 nt long), causing the activa-
tion of a weak cryptic site 1180 nt downstream262. There are several 
other stronger candidate cryptic splice sites that occur between the 
natural and cryptic splice site, but there is no evidence that any are 
used in the individual carrying this mutation.
Designate genic rearrangements (insertions, deletions, 
duplications) with genomic coordinates
Complex insertions and deletions in IVS or c. notation may occa-
sionally be parsed to the wrong coordinates within a gene. Indels 
will parse properly when genomic coordinates are used. If IVS or 
c. notation is used, it is suggested that users confirm that the 
expected alteration of the mutation is correct by reviewing the 
sequence walker display generated by ASSEDA for all insertions, 
deletions and duplications.
Dataset 1. New dataset for mRNA splicing mutations in genetic 
disease
http://dx.doi.org/10.5256/f1000research.5654.d43956
Dataset for mRNA splicing mutations in genetic disease. All data 
from the extensive review of the literature presented in the article 
are reported as Supplementary tables 1 through 10. The following 
data are provided: 1) articles referring to information theory as a 
tool for splice site mutation analysis; 2) complete list of reviewed 
variants; 3) indels, duplications and multinucleotide variants;  
4) deleterious natural site variants; 5) splicing mutation calculator 
data; 6) Benign Natural Site Variants; 7) branch-point variants;  
8–10) Types 1–3 cryptic splice site variants; 11) validated variants.
Data availability
F1000Research: Dataset 1. New dataset for mRNA splicing muta-
tions in genetic disease, 10.5256/f1000research.5654.d43956263
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The Splicing Mutation Calculator (SMC) is available at http://
splicemc.cytognomix.com.
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The paper by Caminsky is a welcome and timely review of the complexities of pre-mRNA splicing,et al. 
the relationship between splicing mutations, detection thereof by IT and/or laboratory, and new
challenges posed by next generation sequencing.
It is a rather lengthy and somewhat intimidating review, and I can imagine that many readers, even
interested ones, may not make it all the way to the end, certainly not in one session. On the other hand,
the review paper is likely to reside on the desk of molecular laboratory directors and and other genetics
professionals with an interest in the molecular aspects of genetics.
The review is well written, and the order to topics discussed is logical. Maybe the introduction to splicing
is a little short, e.g. little space is dedicated to discussing the spliceosome. The review of the various
splice 'sensing' software, and the technology underlying these was in depth.
The relationship between IT predicting splice mutations and laboratory studies to confirm the actual
results of aberrant splicing was very well done, and the discussion of NMD and other causes of technical
issues relating to demonstrating mutant mRNA resulting from splicing mutations was delightful.
The discussion about laboratory standards (also related to ACMG recommendations) regarding splicing
was excellent.
Lastly, the discussion of the impact of splicing mutations and IT in the era of large datasets, including
NGS was concise and accurate.
In summary, this review ought to be mandatory reading for all genetics professionals in molecular
laboratories, incl. those involved in whole exome/genome sequencing.
The figures were well-selected, and the tables were helpful.
One minor remark: I would mention PLP1 as the gene associated with Pelizaeus-Merzbacher disease
(p6, R, middle para).
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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While we agree that a detailed understanding of the mechanisms underlying splicing is
important to include, we have opted to guide the reader to other pertinent reviews on the
spliceosome and relevant mechanisms, so as to not extend the length of this already
lengthy article (modifications have been made to the Introduction – p.3 second paragraph
on left panel). We do not discuss this in detail later on in the review. We have chosen to
provide more details on components and processes of splicing that we later discuss in our
review, such as splicing regulatory factors, donor and acceptor sites, the branch-point, etc.
We have stated that  is the gene associated with Pelizaeus-Merzbacher disease (p6,PLP1
R, middle para). This prompted us to do the same for other diseases and genes that were
mentioned throughout the text including:  (neurofibromatosis type 1 disease – p.3 andNF1
p.13),  (hereditary nonpolyposis colon cancer – p.3),  (xeroderma pigmentosum –MSH2 XPC
p.9),  (hypertrophic cardiomyopathy – p.9),  (recessive dystrophicMYBPC3 COL7A1
epidermolysis bullosa – p.15),  (cystic fibrosis – p.15), (hereditaryCFTR BRCA1 
breast/ovarian cancer – p.15),  (Dorfman-Chanarin syndrome – p.16), CGI-58 APOA5
(hypertriglyceridemia – p.16),  (Alzheimer’s disease – p.17),  (familialCYP46A1 APOB
hypobetalipoproteinaemia – p.20).
 No competing interests were disclosed.Competing Interests:
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The manuscript by Caminsky  reviews the use of Information Theory (IT) based tools to predictet al.
splicing and splicing defects and their possible consequences on the matured transcripts. It is well written
and well organized to guide the reader.
Following an introduction covering the basics of the splicing mechanism and signals on the pre-mRNA
used by the spliceosome to define the exonic and intronic sequences, the authors described the
mathematics behind  prediction and then focus on the use of their tools (ASSEDA, SMC andin silico
Shannon pipeline) and their evolution over the past decade. They review the possibilities and limitations
of such tools and compare them to other splicing prediction softwares (HSF, SSF, NNsplice, ESEFinder,
RESCUE-ESE…).
Over the years, IT-based splicing predictions have made progress and the overall rate of predictions
concordant with experimental validations is around 88%. It has thus become a valuable tool for
geneticists and molecular biologists. The authors also list the most common mistakes made by
researchers while using their tools, and the ways to avoid them. They also stress the difficulties in
predicting the consequences of splicing defect in particular cases due to poorly defined ESE/ESS
sequences, combinatorial effects of splicing regulatory proteins (SR proteins and hnRNPs) and large
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predicting the consequences of splicing defect in particular cases due to poorly defined ESE/ESS
sequences, combinatorial effects of splicing regulatory proteins (SR proteins and hnRNPs) and large
exonic sequence which contains a large number of cryptic donor and splice sites and thus their definition
is dependent on the binding of these regulatory proteins.
The manuscript is therefore of great importance for people that use such splicing prediction software as it
presents their possibilities, limitations and the best way to report the results. Experimentally validated
variants, associated with their predictions(should the authors properly report how the prediction was
performed) will help to refine the tools.
Such  tools are even more valuable in a genomic era where large number of variants are identifiedin silico
by deep sequencing (exomes, whole genome sequencing...) some of which being of unknown
significance. Adding better splicing defects prediction (apart from the 2 bp most conserved in the natural
splice sites) to the filters used in the prioritization pipeline of next generation sequencing projects should
be considered.
I therefore recommend the manuscript for indexation without reservations, if small minor issues listed
below can be addressed.
Minor issues :
Figure 5 is not called in the text.
Since the journal uses a numbered formatting style for the references, please add the number of
the reference in sentences like “Smaoui  2004 described….” (page 17), since it is easier toet al.
find the given reference among over 260.
In the supplementary table 2, in the column “concordance (Y/N)” there is in some cases a “P”
indicated whose meaning is not clear.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 27 Feb 2015
, University of Western Ontario, CanadaPeter Rogan
We have included a paragraph describing Figure 5 (p. 12, right panel).
We have included a numerical reference at the end of each sentence that contains a cited
reference in the text.
Tables that contain the entry “P” in the “Concordance” column has been altered. The
column header “Concordance (Y/N/P)*” is described by the key,“Y: Yes; N: No; P: Partial,”
in the legend.
 No competing interests were disclosed.Competing Interests:
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The Splicing Mutation Calculator web software associated with this publication has been migrated to the
MutationForecaster system (http://mutationforecaster.com).
 MutationForecaster is a subscription-based software product offered byCompeting Interests:
Cytognomix Inc.
Reader Comment 08 Apr 2015
, University of Western Ontario, CanadaPeter Rogan
Video tutorials are now available describing how to use and interpret results from the MutationForecaster
system. (Credits: Ben Shirley, Shannon Brown).
http://mutationforecaster.com/videos.php
 MutationForecaster has been developed by Cytognomix Inc. As indicated in theCompeting Interests:
article, I am one of the founders of the company.
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The paper is very interesting and well written.
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